Platelet glycoprotein IIb/IIIa PlA2/PlA2 homozygosity associated with risk of ischemic cardiovascular disease and myocardial infarction in young men: The Copenhagen City Heart Study

Journal of the American College of Cardiology

Volumn 42, Issue 4, 2003, Pages 661-667

  Bojesen, Stig E ^a   Juul, Klaus ^a   Schnohr, Peter ^b   Tybjærg Hansen, Anne ^b,c   Nordestgaard, Børge G ^a,b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTE AGGREGATION;

EID: 0041730624     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00781-2     Document Type: Article

References (28)

1. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-9.
2. Reiner AP, Siscovick DS, Rosendaal FR. Platelet glycoprotein gene polymorphisms and risk of thrombosis: facts and fancies. Rev Clin Exp Hematol 2001;5:262-87.
3. Weiss EJ, Bray PF, Tayback M, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996;334:1090-4.
4. A2 and coronary risk: a meta-analysis. Thromb Haemost 2001;85:626-33.
5. A1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997;349:385-8.
6. A2 allele and incidence of coronary heart disease - results from the Atherosclerosis Risk In Communities (ARIC) study. Circulation 2000;102:1901-5.
7. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Sorensen TI, Jensen G, Tybjærg-Hansen A. ACE gene polymorphism: ischemic heart disease and longevity in 10,150 individuals. A case-referent and retrospective cohort study based on the Copenhagen City Heart Study. Circulation 1997;95:2358-67.
8. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Jensen G, Tybjærg-Hansen A. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation 2000;101:1907-12.
9. Agerholm-Larsen B, Tybjærg-Hansen A, Schnohr P, Steffensen R, Nordestgaard BG. Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: the Copenhagen City Heart Study. Circulation 2000;102:2197-203.
10. Frikke-Schmidt R, Tybjærg-Hansen A, Steffensen R, Jensen G, Nordestgaard BG. Apolipoprotein E genotype: ε32 women are protected while ε43 and ε44 men are susceptible to ischemic heart disease. The Copenhagen City Heart Study. J Am Coll Cardiol 2000;35:1192-9.
11. Tybjærg-Hansen A, Steffensen R, Meinertz H, Schnohr P, Nordestgaard BG. Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N Engl J Med 1998;338:1577-84.
12. Wittrup HH, Nordestgaard BG, Sillesen H, Schnohr P, Tybjærg-Hansen A. A common mutation in lipoprotein lipase confers a 2-fold increase in risk of ischemic cerebrovascular disease in women but not in men. Circulation 2000;101:2393-7.
13. Andersen TF, Madsen M, Jørgensen J, Mellemkjær L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999;46:263-8.
14. Management of stable angina pectoris. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 1997;18:394-413.
15. Sethi AA, Tybjærg-Hansen A, Grønholdt ML, Steffensen R, Schnohr P, Nordestgaard BG. Angiotensinogen mutations and risk for ischemic heart disease, myocardial infarction, and ischemic cerebrovascular disease. Six case-control studies from the Copenhagen City Heart Study. Ann Intern Med 2001;134:941-54.
16. Zimrin AB, Gidwitz S, Lord S, et al. The genomic organization of platelet glycoprotein IIIa. J Biol Chem 1990;265:8590-5.
17. Ma J, Hennekens CH, Ridker PM, Stampfer MJ. A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study. J Am Coll Cardiol 1999;33:1347-52.
18. Maresca G, Di Blasio A, Marchioli R, Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol 1999;19:1368-77.
19. A2 polymorphism - the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 1999;19:1142-7.
20. A polymorphisms display different sensitivities to agonists. Circulation 2000;101:1013-8.
21. A polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation. Arch Pathol Lab Med 2001;125:112-5.
22. Ardissino D, Mannucci PM, Merlini PA, et al. Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood 1999;94:46-51.
23. Zimmerman FH, Cameron A, Fisher LD, Ng G. Myocardial infarction in young adults: angiographic characterization, risk factors and prognosis (Coronary Artery Surgery Study Registry). J Am Coll Cardiol 1995;26:654-61.
24. 3 enhances outside-in signaling and adhesive functions. J Clin Invest 2000;105:793-802.
25. A polymorphism in the progression of abdominal aortic atherosclerosis. Atherosclerosis 1999;147:55-60.
26. A1/A2 polymorphism and sudden cardiac death. J Am Coll Cardiol 2000;36:1317-23.
27. A polymorphism associates with progression of coronary artery disease and with myocardial infarction in an autopsy series of middle-aged men who died suddenly. Arterioscler Thromb Vasc Biol 1999;19:2573-8.
28. 3 integrin) PlA polymorphism in the early development of coronary atherosclerosis. Atherosclerosis 2001;154:721-7.